It is essential to develop new carriers for laryngeal drug delivery in light of the lack of therapy in laryngeal related diseases. When the inhalable micron-sized crystals of γ-cyclodextrin metal-organic framework (CD-MOF) was utilized as dry powder inhalers (DPIs) carrier with high fine particle fraction (FPF), it was found in this research that the encapsulation of a glycoside compound, namely, scutellarin (SCU) in CD-MOF could significantly enhance its laryngeal deposition. Firstly, SCU loading into CD-MOF was optimized by incubation. Then, a series of characterizations were carried out to elucidate the mechanisms of drug loading. Finally, the laryngeal deposition rate of CD-MOF was 57.72 ± 2.19% improved by SCU, about two times higher than that of CD-MOF, when it was determined by Next Generation Impactor (NGI) at 65 L/min. As a proof of concept, pharyngolaryngitis therapeutic agent dexamethasone (DEX) had improved laryngeal deposition after being co-encapsulated with SCU in CD-MOF. The molecular simulation demonstrated the configuration of SCU in CD-MOF and its contribution to the free energy of the SCU@CD-MOF, which defined the enhanced laryngeal anchoring. In conclusion, the glycosides-like SCU could effectively enhance the anchoring of CD-MOF particles to the larynx to facilitate the treatment of laryngeal diseases.

鉴于喉相关疾病缺乏治疗方法，开发新的喉部给药载体至关重要。当γ的可吸入微米级晶体-环糊精金属有机骨架（CD-MOF）被用作具有高细颗粒分数（FPF）的干粉吸入器（DPI）载体，在本研究中发现糖苷化合物，即灯盏花乙素（SCU）的包封在 CD-MOF 中可显着增强其喉部沉积。首先，通过孵育优化 SCU 加载到 CD-MOF 中。然后，进行了一系列表征以阐明载药机制。最后，当通过下一代撞击器 (NGI) 以 65 L/min 测定时，SCU 使 CD-MOF 的喉部沉积率提高了 57.72 ± 2.19%，大约是 CD-MOF 的两倍。作为概念验证，咽喉炎治疗剂地塞米松 (DEX) 在 CD-MOF 中与 SCU 共同封装后改善了喉部沉积。分子模拟证明了 SCU 在 CD-MOF 中的构型及其对 SCU@CD-MOF 自由能的贡献，这定义了增强的喉部锚定。综上所述，糖苷类SCU可有效增强CD-MOF颗粒对喉部的锚定，促进喉部疾病的治疗。